Most evidence supporting systemic therapy for atopic dermatitis (AD) is derived from randomized clinical trials (RCTs) performed outside the United States, particularly in Europe. However, the US population vastly differs from that of Europe and other regions, with greater racial and ethnic diversity and heterogeneity. This is not a trivial point given recent studies demonstrating greater prevalence 1 and severity of AD and quality-of-life impairment 2 from AD in blacks. Furthermore, blacks have a distinct clinical presentation with a micropapular, perifollicular erythematous eruption. 3 They also seem to have different genetic polymorphisms underlying their disease. 4,5 Yet, little is known about the efficacy of systemic AD therapy in blacks. It is estimated that blacks will represent 13.4% of the US population in the year 2020. It is therefore imperative to determine which treatments work best in them and other sociodemographic groups. The aims of this study were to identify US studies involving systemic AD therapy and assess for racial differences in treatment responses.
It is therefore imperative to determine which treatments work best in them and other sociodemographic groups. The aims of this study were to identify US studies involving systemic AD therapy and assess for racial differences in treatment responses.
Methods | We searched PubMed, EMBASE, Cochrane Library, and GREAT databases from 1898 to 2014 for all studies involving "atopic dermatitis," "atopic eczema," "phototherapy," "UV," "cyclosporine," "cyclosporin," "ciclosporin," "azathioprine," "methotrexate," and "mycophenolate." Only US studies were chosen. We anticipated a small number of studies and therefore decided a priori to include all studies irrespective of study design. Exclusion criteria included studies with fewer than 5 patients with AD and those without efficacy data. The study was approved by the institutional review board at Northwestern University.
Results | A total of 18 studies in the United States concerning systemic AD therapy were identified, of which 9 were excluded (Figure) . Of the 9 remaining, 3 were longitudinal prospective studies, and 6 were cross-sectional retrospective studies. The sample size of patients with AD ranged from 5 to 28. Overall, narrowband UV, low-dose UV-A and UV-B, cyclosporine, mycophenolate mofetil, and azathioprine all resulted in good clinical improvement and/or clearance (Table) . Surprisingly, only 2 studies reported data on treatment responses in different races or ethnicities (Table) . One study of cyclosporine showed that 1 black individual had poorer response than 5 white patients; however, her dose had been reduced owing to the adverse effect of hypertension. A retrospective study of treatment with azathioprine followed by mycophenolate mofetil reports that whites and nonwhites were equally likely to have switched from azathioprine to mycophenolate mofetil.
Discussion | The present study highlights a major deficiency in the reporting of RCT outcomes for AD. There is a dearth of studies demonstrating efficacy of systemic therapy in different racial and ethnic subsets of either children or adults with AD in the United States. Furthermore, the results of our review raise intriguing questions about the generalizability of the results of the extant literature. A fundamental principle of all study designs is to determine whether the study cohort, and by extension the results of the study, is representative of the population. It is difficult to make such conclusions, because most studies did not describe their cohorts in much detail.
Most US studies have been retrospective cross-sectional studies with small sample sizes (the largest had 28 patients), and none were RCTs. These and other weaknesses limit their utility in guiding clinical decision-making for treating recalcitrant AD in racial and ethnic minorities in the United States. In addition, systemic AD treatments have a multitude of potentially serious adverse effects, including increased risk of infection and malignant disease; renal, hepatic, and neurological toxic effects; hypertension; and anemia and other hematologic abnormalities. Currently, we are lacking crucial data to allow for accurately weighing the benefits of treatment against the risks of adverse effects. It is imperative that large-scale RCTs of systemic treatment for AD that include racial and ethnic diversity be conducted in the United States. 
Invited Commentary | PRACTICE GAPS The Lack of Information in Racial and Ethnic Minorities and Their Response to Therapeutics
Every schoolchild in the United States learns the line from the Declaration of Independence that "all men are created equal." The aforementioned statement addresses certain inalienable rights. Yet, from a medical standpoint, are we all the same, do we manifest disease the same way, and do we respond to treatments equally?
In the past, clinical trials were conducted on limited populations, and extrapolations were made to the entire community. Yet, it is becoming clear from studies outside dermatology that different populations may respond differentially to therapeutic interventions. Men and women, for instance, do not respond equally to low-dose aspirin for prevention of cardiovascular and cerebrovascular disease. 1 Racial differences do occur and are meaningful in the response to antihypertensive agents. 2 In the current issue of JAMA Dermatology, Bhattacharya and Silverberg 3 systematically examined the efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. In short, there is almost no evidence that any of the agents studied by the investigators are effective, safe, more effective, or less effective in these minority populations. Because nearly 30% of the US population is nonwhite and this proportion is increasing over time, this presents a major practice gap. In addition, these studies are read around the world, yet the studies from Europe and the United States may not be representative of the population that the reader in Africa or South Asia may treat. Why do we know so little about these populations? Certainly there are well-known disparities in access to health care among the economically disadvantaged. Perhaps clinical studies are conducted in geographic areas in which there may be limited numbers of minority participants. Could there be other social barriers decreasing access to investigative care? Will the advent of more universal health care change this framework?
As we move into the next century of investigation, overcoming the information gap will involve researchers and companies recruiting nonwhite and Hispanic populations into studies of atopic dermatitis and other major skin conditions. We should not assume that the efficacy and safety of agents will be uniform across the rainbow of the population. Moreover, investigators should be aware that there remains confusion in collection and reporting of demographic data that is easily overcome. For instance, the US Census Bureau collects racial information as well as ethnicity (Hispanic or Latino [H/L]) vs not-H/L, yet countless studies report "Hispanic" as a race. Readers should note that there are H/L Asians, H/L blacks, H/L American Indians, etc. Until correct information is gathered and reported, our ability to discern therapeutically important differences remains hampered.
I encourage those performing work in the area to work to recruit minorities, carefully evaluate them, and then report the effects and adverse effects. Through this approach, we will undoubtedly discover that there are differences that improve our patients' quality of life.
Alan B. Fleischer Jr, MD
Author Affiliation: Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Binding of the Trichodysplasia Spinulosa-Associated Polyomavirus Small T Antigen to Protein Phosphatase 2A: Elucidation of a Potential Pathogenic Mechanism in a Rare Skin Disease
Trichodysplasia spinulosa is a disfiguring skin disease caused by the trichodysplasia spinulosa-associated polyomavirus (TSPyV).
1 Like other polyomaviruses, TSPyV expresses the large T and small T (sT) antigens, but how these proteins regulate trichodysplasia spinulosa pathogenesis is unknown. In the closely related human pathogen Merkel cell polyomavirus, sT acts as a transforming oncoprotein in vitro because it alone is sufficient to transform rodent fibroblast cells. 2 Interestingly, this mechanism does not seem to involve protein phosphatase 2A (PP2A), which is a characteristic target of other polyomaviruses' sT antigens. Because PP2A regulates important cellular pathways, the inactivation is one of the critical steps in the polyomavirus pathomechanism. The primary purpose of this study was to determine whether TSPyV sT antigen was capable of binding PP2A; if positive, this finding would implicate specific pathways in trichodysplasia spinulosa pathogenesis.
Methods | Institutional review board requirements were waived for the present work.
Cell Culture and Cell Line Expressing TSPyV sT Antigen. The target TSPyV sT sequence was subcloned into a LentiVector containing a red fluorescent protein-blasticidin selection marker (GenTarget Inc), and the vector was then used to generate a tetracycline-inducible cell line expressing TSPyV sT antigen in HEK293 host cells. The expression of the TSPyV sT antigen was detected by Western blotting using a mouse monoclonal antibody (clone ID 2E10B11, GenScript Inc, 1:100).
